Kohmann Bosshard Financial Services LLC Decreases Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Kohmann Bosshard Financial Services LLC reduced its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 33.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 529 shares of the medical research company’s stock after selling 270 shares during the quarter. Kohmann Bosshard Financial Services LLC’s holdings in Thermo Fisher Scientific were worth $275,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Legacy Investment Solutions LLC purchased a new stake in shares of Thermo Fisher Scientific during the 3rd quarter worth $26,000. Peterson Financial Group Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 3rd quarter worth $27,000. Barrett & Company Inc. purchased a new stake in Thermo Fisher Scientific in the fourth quarter valued at about $28,000. FPC Investment Advisory Inc. purchased a new stake in Thermo Fisher Scientific in the fourth quarter valued at about $28,000. Finally, Missouri Trust & Investment Co purchased a new stake in Thermo Fisher Scientific in the fourth quarter valued at about $29,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 9,825 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the sale, the chief financial officer now owns 27,296 shares in the company, valued at $15,984,264.64. The trade was a 26.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $530.26, for a total value of $5,302,600.00. Following the completion of the sale, the chief executive officer now owns 111,192 shares in the company, valued at $58,960,669.92. This represents a 8.25 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 20,125 shares of company stock worth $11,231,699. 0.34% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Stock Up 1.1 %

Thermo Fisher Scientific stock opened at $528.99 on Friday. The firm has a market cap of $199.57 billion, a price-to-earnings ratio of 32.00, a price-to-earnings-growth ratio of 2.99 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 52 week low of $493.30 and a 52 week high of $627.88. The business’s 50-day moving average price is $549.37 and its 200 day moving average price is $565.17. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific announced that its Board of Directors has authorized a share buyback plan on Friday, November 15th that permits the company to repurchase $4.00 billion in shares. This repurchase authorization permits the medical research company to purchase up to 2% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s management believes its stock is undervalued.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be given a dividend of $0.43 per share. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a yield of 0.33%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.41%.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on TMO shares. Scotiabank increased their price target on Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a “sector perform” rating in a research note on Monday, February 3rd. Citigroup increased their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company a “neutral” rating in a research note on Friday, January 31st. Bank of America decreased their price target on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Wells Fargo & Company increased their price target on Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an “overweight” rating in a research note on Friday, January 31st. Finally, UBS Group raised their price objective on Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a “buy” rating in a research note on Friday, January 31st. Four equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $656.86.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.